Managing Comorbidities and Coinfections in HIV: Interview With Rajesh T. Gandhi, MD
Rajesh T. Gandhi, MD, discusses management of coinfections, including HPV and sexually transmitted infections, in people with HIV.
IDWeek 2017
Antibiotic Stepdown Tx for Uncomplicated Gram-Negative Bloodstream Infections
For uncomplicated Gram-negative bloodstream infections, oral beta-lactam therapy may be an appropriate stepdown option.
Inappropriate Antibiotic Prescribing Rates High for Uncomplicated UTIs
Inappropriate prescribing of outpatient antibiotics for the treatment of uncomplicated urinary tract infections are higher than previously estimated.
Isoniazid-Rifapentine for Latent TB Sees High Completion Rates
Isoniazid-rifapentine regimen sees high completion rates for latent tuberculosis infection.
Efficacy of Continuous vs Intermittent Vancomycin for Pediatric MRSA Infections Evaluated
Vancomycin administered via continuous infusion was found to achieve the recommended VAN trough of 15-20mg/L faster and with less risk of adverse events compared to administration via intermittent infusion.
Incidence of STI in PrEP Users Who Report Alcohol/Drug Use
The aim of this study was to identify and characterize PrEP patients who remain at high risk for HIV as demonstrated by STI diagnosis after starting PrEP.
Infant Gut Microbiome Altered by Maternal Antibiotic Use
Mothers’ use of antibiotics affects infant gut composition up to a month later.
Safety, Efficacy of TAF vs TDF in HIV+ Adults Stratified by Race
Among HIV-infected, virologically suppressed black adults, FTC/TAF showed improvements in renal and bone safety compared to FTC/TDF.
Frequent Syphilis Screening Necessary for High-Risk Populations
In 2004, syphilis screening guidelines were changed to recommend rapid plasma regain testing every 3 to 6 months.
Latent Tuberculosis May Benefit From 3-Month Rifapentine, Isoniazid Tx
Three months of rifapentine + isoniazid using directly observed therapy resulted in a higher completion rate and no loss of follow-up for latent tuberculosis.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in IDWeek 2017
Loading... 
Loading...